Xbrane Biopharma Ab · OMXSTO:XBRANE
Xbrane Biopharma Ab — Q1 2026 Earnings Presentation
19 slides from Xbrane Biopharma Ab's earnings presentation, May 5, 2026
Slide 1: Q1 2026 presentation
RANE BIOPHARMA Science for high quality biosimilars RANE BIOPHARMA Q1 2026 presentation MBRANE SCIENCE FOR HIGH QUALITY BIOSIMILARS
Slide 2: Ximluci BLA re-submitted
“Ximluci BLA re-submitted” Martin Amark, CEO May 5", 2026 y YBRANE SCIENCE FOR HIGH QUALITY BIOSIMILARS January - Mars 2026 Interim Report 2026.05.05.
Slide 3: Disclaimer
Disclaimer You must read the following before continuing, The following applies to this document and the information provided in this presentation by Xbrane Biopharma AB (publ) (the "Company’) or any person on behalf of the Company and any ‘other material distributed or statements made in connection
Slide 4: Presenters
Presenters P Martin Amark Jane Benyamin CEO CFO MBRANE SCIENCE FOR HIGH QUALITY BIOSIMILARS January jars 2026 Interim Report 2026.
Slide 5: Ximluci – Launched across 24 countries
Ximluci® – Launched across 24 countries Ximluci® launched by STADA in 24 countries Co-Development & Commercialization Partnership with STADA Partnership with STADA signed in 2018. STADA are granted the commercial rights to Ximluci® globally Global generics and biosimilar specialist with including
Slide 6: Ximluci addressable market in Europe is €5 billion
Ximluci® addressable market in Europe is €5 billion Europe retinal anti VEGF: EUR 5 billion market Commentary Europe retinal anti VEGF market at €5 billion in 2024 with € 5 billion approx. 7 million units (excl off label Avastin) shipped 100% Volume growth of 7% p.a. and value growth of 5.5% p.a
Slide 7: Ximluci – Currently at 8% volume market share in Europe
Ximluci® – Currently at 8% volume market share in Europe Profit split to Xbrane and growth in vials sold by STADA Commentary Ximluci® share of ranibizumab market across launched countries in Europe was 8% by volume in March 2026 Constant cash profit sharing Q1 2026 vs. Q4 2025 despite lower volu
Slide 8: Lucamzi – delay in FDA approval
Lucamzi – delay in FDA approval Xbrane & STADA partner with Valorum US Commercialization Partnership Xbrane and STADA license US commercial rights to Valorum Biologics. Valorum will be responsible for sales, Biosimilar commercialization marketing and commercial efforts in the US after approval. ST
Slide 9: Xdivane clinical trial initiated and program on track towards day 1 launch
Xdivane clinical trial initiated and program on track towards day 1 launch 2024 2025 2026 2027 2028 2029 2030 Commercialization Milestone payment to Milestone payment to Xbrane Xbrane LoE US LoE Europe Production of clinical material Pivotal clinical trial MAA / BLA Successful scale-up to Single
Slide 10: Amended agreement on financing of Xdivane with Intas
Amended agreement on financing of Xdivane with Intas • • • •
Slide 11: External valuation of the Xdivane engagement at the time of market launch
External valuation of the Xdivane engagement at the time of market launch Base case forecasted profit sharing to Xbrane Assumptions • • • • • • • • • Source: Venture Valuation AG
Slide 12: Jan-Mar Interim Report 2026
"y | Jan-Mar Interim Report 2026 Financials ~~! - MBRANE SCIENCE FOR HIGH QUALITY BIOSIMILARS January - Mars 2026 Interim Report 2026.05.05.
Slide 13: Net Revenues (Quarter by Quarter)
Net Revenues (Quarter by Quarter) Net revenue Gross margin Commentary on 6 SEK m % Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 +> Revenue Q1 2026 ~ 17,3 MSEK. 00,0 140% 120% > Shipment of product to STADA resumed (at 0 value of 17,2 MSEK). COGS amounting to 6,8 " 100% MSEK. Gross margin amountin
Slide 14: Company Expenses (G&A and R&D) by Quarter
Company Expenses (G&A and R&D inc. capitilized R&D) by Quarter Quarter by Quarter Commentary 26 SEK m Q2'24 Q3'24 04'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 0,0 95 98 10,1 11,0 aa me es -10,0 183 =z FR -20,0 -30,0 is, -40,0 0 > Administration expenses amounted to 7,6 MSEK -50,0 > R&D expenses amounted to 9
Slide 15: Cash flow chart Q1-26
Cash flow chart Q1-26 13 -4 87 -17 -1 -7 67 -3
Slide 16: Cash and Cash Equivalents
Cash and Cash Equivalents Operating Cash Flow
Slide 17: Key Take-Aways
Key Take-Aways Ximluci® launched in 24 countries, constant market share in Europe Ongoing initiatives to reduce Ximluci production cost for long term competitiveness Ximluci BLA resubmitted in April 2026 Xdivane development proceeding according to plan targeting BLA submission H2 2027 MBRANE SCIENCE
Slide 18: Business Concept
BUSINESS CONCEPT Xbrane develops biosimilars of difficult-to- manufacture and often very expensive original drugs VISION To become a world-leading scientifically-based biosimilar developer of cost-effective drugs for which there is a significant medical need OBJECTIVE To contribute to everybody havi
Slide 19: MUBRANE SCIENCE FOR HIGH QUALITY BIOSIMILA
MUBRANE SCIENCE FOR HIGH QUALITY BIOSIMILA January - Mars 2026 Interim Report